Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000298406 encodes a long non-coding RNA classified as a natural antisense transcript (NAT) relative to the CCDC126 gene. NATs are a widespread class of transcripts in eukaryotic genomes; they regulate gene expression in cis or trans, often by interacting with the sense transcript. Mechanisms by which NATs regulate gene expression include transcriptional interference, RNA masking, RNA editing, and gene silencing. However, the specific regulatory activity, physiological function, and expression profile of this particular lncRNA have not been characterized. There is no information indicating that this transcript is a direct therapeutic target or functionally associated with disease at this time. In summary, "novel transcript, antisense to CCDC126" refers to a poorly characterized lncRNA; it is not considered a well-defined therapeutic target, and its functional relevance remains unclear based on current public resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CCDC126 (ENSG00000298406).